Abstract
Blocking the action of FSH genetically or pharmacologically in mice reduces body fat, lowers serum cholesterol, and increases bone mass, making an anti-FSH agent a potential therapeutic for three global epidemics: obesity, osteoporosis, and hypercholesterolemia. Here, we report the generation, structure, and function of a first-in-class, fully humanized, epitope-specific FSH blocking antibody with aKDof 7 nM. Protein thermal shift, molecular dynamics, and fine mapping of the FSH–FSH receptor interface confirm stable binding of the Fab domain to two of five receptor-interacting residues of the FSHβ subunit, which is sufficient to block its interaction with the FSH receptor. In doing so, the humanized antibody profoundly inhibited FSH action in cell-based assays, a prelude to further preclinical and clinical testing.
Funder
HHS | NIH | National Institute on Aging
HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
Publisher
Proceedings of the National Academy of Sciences
Reference59 articles.
1. International Osteoporosis Foundation , Osteoporosis–Incidence and burden. (2016). https://www.iofbonehealth.org/osteoporosis. Accessed 12 October 2020.
2. World Health Organization , Obesity and overweight. (2018). https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight. Accessed 12 October 2020.
3. Minireview: The Link Between Fat and Bone: Does Mass Beget Mass?
4. Is obesity protective for osteoporosis? Evaluation of bone mineral density in individuals with high body mass index
5. The Association of Menopause and Physical Functioning in Women at Midlife
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献